aclimostat (ZGN-1061) / Larimar Therap - LARVOL DELTA

The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized placebo-controlled trial. (PubMed, Diabetes Obes Metab) - "We conclude that MetAP2 inhibition with ZGN-1061 for 12?weeks improved glucose control and aided weight loss in overweight and obese people with type 2 diabetes. However, given safety issues, Zafgen has discontinued MetAP2 inhibitor development."

Clinical • Journal

Inhibition of methionine aminopeptidase 2 enzyme enhances insulin responsiveness in human adipocytes (EASD 2019) - "...Our objective was to examine the direct effect of ZGN-1062 (a MetAP2 inhibitor similar to ZGN-1061) on human adipocyte function in vitro.Materials and Biopsies of the abdominal subcutaneous region (SAT, n=6) were performed in individuals participating in institutional clinical studies at the Translational Research Institute for Metabolism and Diabetes... Inhibition of MetAP2 in differentiated adipocytes enhances insulin suppression of lipolysis, thus inhibiting free fatty acid release which can be one of the mechanisms by which MetAP2 inhibition might lead to improvements in glycemic control in vivo.Clinical Trial Registration Number: N/A"

Final Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the MetAP2 Inhibitor ZGN-1061 in Patients with Type 2 Diabetes (ADA 2019) - "There were no reports of venous thrombosis or changes in thrombosis markers indicative of a thrombosis event. ZGN-1061 (1.8 mg) demonstrated statistically significant and clinically meaningful efficacy; the largest reductions in A1C and weight were observed at 12 weeks with no evidence of a waning effect and no notable safety signals."

Clinical • P2 data

The MetAP2 Inhibitor, ZGN-1061, Improves Insulin Sensitivity and Beta-Cell Function in Patients with Type 2 Diabetes (ADA 2019) - "In patients with T2D, improved glycemic control with ZGN-1061 may be driven by changes in insulin sensitivity and β-cell function. These results support future assessments using other definitive methods."

Clinical • Late-breaking abstract